NTRK3 and neoplasm: Clinically, these markers show liquid biopsy potential: ctDNA-based detection monitors immune microenvironment dynamics [66], IGSF10 promoter methylation may enable non-invasive early diagnosis [67], and peripheral blood NTRK3 fusion detection correlates with tumor burden [56], paralleling molecular barcode monitoring in pancreatic/biliary malignancies [68].